





































What is the relevance of an ambulatory quick
diagnosis unit or inpatient admission for the
diagnosis of pancreatic cancer? A retrospective
study of 1004 patients
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Abstract
Quick diagnosis units (QDU) have become an alternative hospital-based ambulatory medicine strategy to inpatient hospitalization for
potentially serious illnesses in Spain. Whether diagnosis of pancreatic cancer is better accomplished by an ambulatory or inpatient
approach is unknown. The main objective of this retrospective study was to examine and compare the diagnostic effectiveness of a
QDU or inpatient setting in patients with pancreatic cancer.
Patients with a diagnosis of pancreatic adenocarcinoma who had been referred to a university, tertiary hospital-based QDU or
hospitalized between 2005 and 2018 were eligible. Presenting symptoms and signs, risk and prognostic factors, and time to
diagnosis were compared. The costs incurred during the diagnostic assessment were analyzed with a microcosting method.
A total of 1004 patients (508 QDU patients and 496 inpatients) were eligible. Admitted patients were more likely than QDU patients
to have weight loss, asthenia, anorexia, abdominal pain, jaundice, and palpable hepatomegaly. Time to diagnosis of inpatients was
similar to that of QDU patients (4.1 [0.8 vs 4.3 [0.6] days; P= .163). Inpatients were more likely than QDU patients to have a tumor on
the head of the pancreas, a tumor size>2cm, a more advanced nodal stage, and a poorer histological differentiation. No differences
were observed in the proportion of metastatic and locally advanced disease and surgical resections. Microcosting revealed a cost of
€347.76 (48.69) per QDU patient and €634.36 (80.56) per inpatient (P< .001).
Diagnosis of pancreatic cancer is similarly achieved by an inpatient or QDU clinical approach, but the latter seems to be cost-
effective. Because the high costs of hospitalization, an ambulatory diagnostic assessment may be preferable in these patients.
Abbreviations: 95% CI = 95% confidence intervals, AJCC= American Joint Committee on Cancer, ALT/SGPT = alanine
aminotransferase, AST/SGOT = aspartate aminotransferase, CA19.9 = carbohydrate antigen 19.9, CEA = carcinoembryonic
antigen, CRP = C-reactive protein, CT = computed tomography, ECOG = Eastern Cooperative Oncology Group, ED = emergency
department, EUS = endoscopic ultrasound, LDH = lactate dehydrogenase, OR = odds ratio, PC = primary care, QDU = quick
diagnosis unit, ROC = receiver-operating-characteristic.
Keywords: diagnosis, emergency department, inpatient, length of stay, outpatient, pancreatic adenocarcinoma, pancreatic
cancer, primary care, time to diagnosis
1. Introduction
With a 5-year-life expectancy of 5%, the prognosis of pancreatic
cancer has remained practically unchanged over the last 20
years.[1] The low survival rates can be attributed to several factors
but mainly the late stage at which the condition manifests and a
diagnosis is made. The majority of patients will have metastasis
or a locally advanced disease in the asymptomatic phase and,
even after surgery for cure, most will have recurrence.[1,2] Because
there are no effective screening methods for early detection, a
high degree of suspicion remains decisive to make a diagnosis,
especially by primary care (PC) physicians who are usually the
first to see the patient. Yet diagnosis can be challenging.[1,3,4]
Since early symptomsmay be nonspecific, vague, and intermittent
(eg, weight loss, nonspecific abdominal pain) and often attributed
to coexisting disorders or ageing, diagnosis is commonly
delayed.[1,5–8] In fact, the total diagnostic interval (ie, from
onset of symptoms to diagnosis) of pancreatic cancer is longer
than the interval of other cancers including other hard-to-suspect
cancers. Due to the poor specificity of symptoms and delayed
diagnosis, some experts have recommended to improve the
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diagnostic skills of PC physicians when caring for patients with
an eventual diagnosis of pancreatic cancer.[9–11]
Delays in the diagnosis of suspected serious diseases in patients
attending PC centers or hospital outpatient clinics are not
uncommon in countries with public healthcare systems. Indeed,
mostly owing to delayed investigations ordered by PC physicians,
patients with suspected cancer, even with an appropriate
performance status, have been traditionally hospitalized to
speed-up diagnosis.[12,16,17] However, admission for diagnostic
workup of such patients may only increase the costs of
hospitalization, contributing to increased expenditures in health-
care. To avoid delays and potentially avoidable admissions, the
Spanish healthcare system created in the 2000s hospital based-
ambulatory facilities called quick diagnosis units (QDUs).[12]
Compared to conventional hospitalization for workup, these
clinics have various advantages. In addition to a time to diagnosis
similar to the length-of-stay for similar conditions, QDUs are
useful to decrease referrals from PC to emergency departments
(EDs), are cost-saving, and are associated with higher patients’
satisfaction scores than hospitalization.[12–15]
Since an adequate performance status argues in theory against
admission of patients who are eventually diagnosed with
pancreatic cancer, QDUs may be a suitable setting for their
evaluation. However, no study has evaluated how a QDU
compares to an inpatient setting for its diagnosis. The main
purpose of this study was to investigate the effectiveness and
associated costs of a hospital-based ambulatory QDU versus
inpatient setting for the diagnosis of pancreatic adenocarcinoma.
2. Methods
2.1. Settings
The QDU is based on the Adult Day Care Center of the Hospital
Clínic, a public tertiary university hospital in Barcelona with a
reference population of 550,000. Patients are referred to this unit
from 15 PC centers and the hospital ED. Evaluable disorders and
general characteristics of QDU have been reported elsewhere.[12–
14] In addition, the General Internal Medicine Department of the
hospital has 3 inpatients wards, each with 25 beds, and most
patients are admitted to them from the ED.
2.2. Study population
To analyze a homogeneous population, patients aged ≥18 years
with a diagnosis of pancreatic adenocarcinoma who had been
referred to QDU or hospitalized between October 2005 and
November 2018 were eligible. The study was approved by the
Research Ethics Committee of the Hospital Clínic and need for
written consent was waived due to the retrospective nature of
clinical data.
Pathologists selected and reviewed cytologic and histopatho-
logical (herein referred to as “cyto/pathological”) specimens of
consecutive cases with a diagnosis of pancreatic adenocarcinoma
according to the World Health Organization classification
criteria.[18] Attending and resident physicians from QDU and
inpatient wards reviewed the medical records of all patients and
entered the following data into an electronic database:
(1) referral sources (ED or PC);
(2) demographic and epidemiological data including age, sex,
ethnic race (white or other), and socioeconomic status
(measured by education and income);
(3) domestic situation (living alone or living with partner or
other);
(4) presenting clinical manifestations including presence or
absence of weight loss, asthenia, anorexia, nausea or
vomiting, change in bowel habit, abdominal pain, back
pain, pruritus, lethargy or depression, thrombophlebitis,
jaundice, new-onset diabetes, abdominal mass, hepatomega-
ly, and peripheral lymphadenopathy;
(5) relevant laboratory data (see prognostic factors below);
(6) overall comorbidity according to the age-adjusted Charlson
index (0–4 or 4.1–6 or >6)[19,20];
(7) results from endoscopic and imaging reports including
procedures used to obtain a cyto/pathological diagnosis
(upper gastrointestinal endoscopic ultrasound [EUS]-, ultra-
sound-, and computed tomography [CT]-guided biopsy); and
(8) onward referrals after diagnosis (pancreatic multidisciplinary
unit or hospitalization from QDU or PC or palliative care).
Patients with pancreatic neuroendocrine, intraductal papillary
mucinous, and mucinous cystic neoplasms were excluded as were
patients with ampullary and duodenal tumors through reevalua-
tion of cyto/pathological specimens. Patients with incomplete
clinical or cyto/pathological information, lost to follow-up, or
dead before staging were also excluded.
2.3. Staging
A contrast-enhanced thin-slice CT scan of the chest, abdomen,
and pelvis was performed in all patients to determine the clinical
stage.[21] Specifically, CT scans, and occasionally EUS, were used
to establish the tumor site and size, presence or absence of
metastatic disease, and local relationships of the tumor according
to the American Joint Committee on Cancer (AJCC) (7th Edition
[2010] staging system).[22,23]
2.4. Risk and prognostic factors
Risk factors of pancreatic cancer were compared between QDU
patients and inpatients. These included age (<75 vs ≥75 years),
smoking status (current vs ex-smoker vs never smoker), history of
pancreatitis, family history of pancreatic cancer, bodymass index
(≥35 vs <35kg/m2), long-standing type 2 diabetes mellitus, and
heavy alcohol consumption (<6 vs ≥6drinks/d).[1–3,21,24,25]
When it was not possible to differentiate between acute and
chronic pancreatitis, any history of pancreatitis was considered.
Reported prognostic factors of pancreatic cancer were
recorded including the Eastern Cooperative Oncology Group
(ECOG) performance score (0–<2 vs ≥2–4), primary tumor site
(head vs body/tail), AJCC tumor stage (T1 [2cm] vs T2 [>2
cm]), AJCC nodal stage (N0 vs N1 vs unknown [NX]), AJCC
metastasis stage (M0 vs M1), and overall staging according to
AJCC (resectable stages: I, II, and borderline resectable stage III
subset; unresectable stages: locally advanced stage III subset and
stage IV or metastatic subset).[21,25,26] The grade of differentia-
tion of the specimens obtained by biopsy (well-differentiated,
moderately differentiated, poorly differentiated, or unknown)
and the results of several laboratory parameters formerly
reported to have a potential prognostic role in pancreatic cancer
including serum tumor markers carbohydrate antigen 19.9
(CA19.9) and carcinoembryonic antigen (CEA), lactate dehy-
drogenase (LDH), albumin, white blood cell count, platelet
count, hemoglobin, aspartate aminotransferase (AST/SGOT),
alanine aminotransferase (ALT/SGPT), alkaline phosphatase,
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total bilirubin, blood urea nitrogen, creatinine, and C-reactive
protein (CRP) were also compared.[27–39] In patients with a total
bilirubin level ≥2.0mg/dL (ie, presumed altered biliary excre-
tion), CA19.9 and CEA concentrations were adjusted by dividing
their level by the total bilirubin level. In patients with normal
biliary excretion (ie, total bilirubin level <2.0mg/dL), the actual
tumor marker concentration was used.[27,33]
Surgical characteristics of patients who underwent resection
were analyzed. These characteristics included age and sex at time
of surgery, presence or absence of preoperative jaundice, total
bilirubin level >20mg/dL, need for preoperative endoscopic
biliary stenting, resectability according to the AJCC staging
system,[21] primary tumor site on surgical resection, tumor size,
nodal stage, histological grade, vascular, lymphatic, and
perineural invasion by microscopically evaluated surgical speci-
mens,[34] adjusted preoperative level of CA19.9, and resection
margins on microscopically assessed specimens (negative or R0
resection: absence of tumor cells within 1mm of the resection
margin; positive or R1 resection: microscopically positive at
margin or tumor within 1mm of the margin).[2,31,34]
2.5. Waiting times
Waiting times between referral and appointment ofQDUpatients
and admission of inpatients, QDU time to diagnosis in QDU
patients and length-of-stay in inpatients were calculated. To
allow for an equivalent measure of QDU time to diagnosis versus
length-of-stay and associated costs between QDU and inpatient
wards, QDU time to diagnosis and admission (instead of length-
of-stay) time to diagnosis were defined as the time elapsed
between the request of the decisive diagnostic procedure and the
cyto/pathological diagnosis. This was done because patients with
pancreatic cancer may require hospitalization not only to
expedite diagnosis but also for management of symptoms. Thus,
to control for the imbalance in patient- and pancreatic cancer-
related characteristics that may bias the outcome comparisons,
these intervals, instead of the full time until discharge, were
considered a better reflection and comparable measure of the time
to diagnosis between the 2 groups.
2.6. Patient factors associated with hospitalization
In a separate analysis, the potential independent predictors of
emergency admission against ED referral to QDU were
determined. A literature review was performed to identify
candidate explanatory variables that could be associated with
unplanned emergency admission in patients with pancreatic
cancer or other types of cancer.[40] Associations between this
outcome and the explanatory variables were tested using first
univariate and then multivariate analysis (see Statistical analysis).
2.7. Resource use data collection and cost analysis
Costs of QDU patients and inpatients were analyzed and
compared with the microcosting method, often considered a
paradigm of hospital service costs since all relevant cost
components are determined.[41–43] The microcosting methodol-
ogy used by us for other disorders has been described
elsewhere.[13,16,44,45] In brief, resource use for each patient
evaluated was obtained. Resource use data included diagnostic
examinations, pharmaceuticals and consumables, therapeutic
procedures, adverse events, and consultations. Only treatments
other than pancreatic cancer-specific treatments (ie, treatment of
patients’ symptoms) were included in the analysis. Costs of all
individual resource items were obtained from the institutional
information system of the hospital. For QDU patients, the cost of
an average ambulatory consultation corresponded to Catalan
Health Service fees. The cost of examinations corresponded to
hospital tariffs and were the same for QDU patients and
inpatients. The analysis also integrated fractions of all staff
wages. Staff at QDU includes a full-time consultant internist, a
senior internal medicine resident, a full-time nurse, a part-time
nurse coordinator, and 2 part-time administrative assistants.
The unit is open 5hours a day, 5 days a week. Staff in each of
the 3 medical wards includes 2 full-time consultant internists, 2
residents, a full-time nurse coordinator, 3 teams of 3 full-time
nurses and 3 teams of 2 full-time nursing assistants (8-hours daily
shifts), and a full-time administrative assistant. Non-direct costs,
which mainly corresponded to structural and general functioning
costs such as costs related to maintenance, laundry, cleaning
services, and administrative costs, as well as depreciation of fixed
costs were included in the final analysis.
The mean number of visits during the QDU evaluation, cost
per visit and cost per QDU patient, and the mean admission time
to diagnosis, cost per day of stay and cost per inpatient were
computed and compared. All costs were adjusted for the year of
collection (2005–2018) to reflect 2018 Euros (€). Final costs and
cost differences are presented in 2018 Euros.
2.8. Statistical analysis
The Chi-square or Fisher exact test were used to compare
categorical variables, and results are reported as absolute
frequencies (%). The t test was used to compare normally
distributed continuous variables and results are expressed as
means with standard deviations. When needed, continuous
variables with skewed distributions were compared with the
nonparametric Mann–Whitney U test. The nature and extent of
missing data was included in the analysis.
For the study of factors associated with emergency admission,
univariate tests were first done to compare patients admitted
versus not admitted on each explanatory variable. Determinants
with a P value <.20 in the univariate analysis were included
in a multivariate logistic regression model and correlations
between covariates were assessed. Collinearity was evaluated for
the independent variables and those variables showing excessive
collinearity were excluded. Because the existing literature
emphasizes that age and sex are important determinants of
admission, these variables were forced into the model irrespective
of the univariate results. A backward selection analysis was done
to construct the final model. Results are expressed as crude and
adjusted odds ratios (ORs) with 95% confidence intervals (95%
CI). The accuracy of the model was evaluated by the area
under the receiver-operating-characteristic (ROC) curve.Reported
P values are 2-sided and statistical significance was established at




Of 1147 eligible patients, 143 were excluded. Figure 1 shows the
number of initially eligible patients from QDU and inpatient
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wards and the causes for their exclusion. The main reason for
exclusion was incomplete clinical information. After exclusion,
1004 patients comprising 508 QDU patients and 496 inpatients
were available for the analysis (Fig. 1). The general characteristics
of the whole population are shown in Table 1. There were
significant differences in the referral sources. While both QDU
patients and inpatients were more commonly referred from the
ED, the QDU was more often used by PC physicians (31.7% of
QDU patients versus 21.4% of inpatients were referred from PC;
P< .001). Themean age of QDUpatients and inpatients was 71.2
(12.8) and 72.5 (13.2) years, respectively, and there was a slight
predominance of males in both groups. No significant differences
were observed in the socioeconomic status. Compared with
inpatients, QDU patients were less likely to live alone and more
likely to live with a partner (21.3 vs 26.6%; P= .024 and 69.7 vs
65.0%; P= .042, respectively). Regarding symptoms and signs on
presentation, admitted patients were significantly more likely
than QDU patients to have weight loss, asthenia, anorexia,
abdominal pain, jaundice, and palpable hepatomegaly of stony
consistency. Whereas some symptoms (nausea/vomiting, change
in bowel habit, pruritus, and new-onset diabetes) never presented
solitarily, the most frequent symptoms presenting solitarily were
abdominal pain, jaundice, back pain, and the triad weight loss,
asthenia, and anorexia. It is of note that 9 (1.8%) QDU patients
and 6 (1.2%) inpatients (all of them with early-stage pancreatic
adenocarcinoma) had no symptoms but their tumor was detected
as an incidental imaging finding on medical check-up or during
evaluation for other diseases.
There were no significant differences in the age-adjusted
Charlson comorbidity score between QDU patients and
inpatients. As to waiting times, the time to admission was
significantly shorter than the time to the first QDU visit (0.7 [0.2]
vs 1.2 [0.3)] days; P< .001) and there were no differences
between the admission time to diagnosis and the QDU time to
diagnosis (4.1 [0.8] vs 4.3 [0.6] days; P= .163). Three patients
had to be admitted to inpatient wards during the QDU
assessment: 2 of them had a quick deterioration of their
performance status as well as increased jaundice and the other
a pulmonary thromboembolism. Table 1 shows the nature and
extent of missing data in both groups of patients. There was a
slight degree of missing data in the variables “Socioeconomic
status,” “Domestic situation,” “Age-adjusted Charlson comor-
bidity index,” and “Waiting times,” which ranged from 0.3% to
1.9% in QDU patients and 0.4% to 2% in inpatients (see
footnote of Table 1).
3.2. Risk and prognostic factors
The frequency of risk factors of pancreatic cancer was slightly
higher in inpatients than in QDU patients, but no significant
differences were observed (Table 2). Table 3 shows the frequency
of prognostic factors. Although the head of the pancreas was the
most frequent primary tumor site in the 2 groups of patients,
67.7% of inpatients versus 62.6% of QDU patients had a tumor
on this localization (P= .032). Inpatients were also more likely
than QDU patients to have a mean tumor size >2cm (77.0 vs
72.4%; P= .048), an N1 stage (75.6 vs 70.9%; P= .049), and a
poorer grade of histological differentiation (26.2 vs 21.1%;
P= .031). Moreover, 61.5 vs 59.1% of inpatients and QDU
patients, respectively, had a metastatic stage on presentation
(P= .120) and 29.4 versus 29.1% of inpatients and QDU
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Figure 1. Flowchart of patients included in the study. QDU=quick diagnosis unit.
Bosch et al. Medicine (2020) 99:11 Medicine
4
Table 1
General characteristics of study patients.
Characteristic QDU patients (n=508) Inpatients (n=496) P-value
Referral source, n (%)
Emergency department 347 (68.3) 390 (78.6) <.001
Primary care 161 (31.7) 106 (21.4) <.001
Age (yr), mean (SD) and n (%) 71.2 (12.8) 72.5 (13.2)
54 30 (5.9) 22 (4.4) .155
55–64 79 (15.6) 69 (13.9) .145
65–74 217 (42.7) 221 (44.6) .135
≥75 182 (35.8) 184 (37.1) .168
Sex, n (%) .206
Females 241 (47.4) 238 (48.0)
Males 267 (52.6) 258 (52.0)
Ethnic race, n (%) .227
White 502 (98.8) 489 (98.6)
Other 6 (1.2) 7 (1.4)
Socioeconomic status
Education, n (%)
No schooling 36 (7.1) 51 (10.3) .094
Primary or lower secondary 198 (39.0) 206 (41.5) .117
Upper secondary or professional training 181 (35.6) 166 (33.5) .129
University 93 (18.3) 73 (14.7) .083
Once-a-month income (€), mean (SD) and n (%)
∗
1482.3 (337.5) 1379.1 (303.4)
900 38 (7.5) 40 (8.0) .212
901–1200 164 (32.3) 162 (32.7) .215
1201–1800 182 (35.8) 175 (35.3) .208
>1800 124 (24.4) 119 (24.0) .236
Domestic situation, n (%)
Living alone, including with children under 18 yr but no adults 108 (21.3) 132 (26.6) .024
Living with partner, +/ children 354 (69.7) 322 (65.0) .042
Other 46 (9.1) 42 (8.5) .204
Presenting symptoms and signs, n (%)
Weight loss 266 (52.4) 285 (57.5) .031
Asthenia 262 (51.6) 279 (56.3) .044
Anorexia 255 (50.2) 274 (55.2) .034
Nausea/vomiting 27 (5.3) 35 (7.1) .139
Change in bowel habit 102 (16.5) 87 (17.5) .210
Abdominal pain 226 (44.5) 244 (49.2) .046
Back pain 143 (28.1) 158 (31.9) .079
Pruritus 114 (22.4) 69 (13.9) <.001
Lethargy/depression 47 (9.3) 63 (12.7) .088
Thrombophlebitis 22 (4.3) 42 (8.5) .062
Jaundice 155 (30.5) 191 (38.5) <.001
New-onset diabetes 13 (2.6) 34 (6.9) .057
Abdominal mass 5 (1.0) 26 (5.2) .060
Hepatomegaly† 20 (3.9) 45 (9.1) .027
Peripheral lymphadenopathy‡ 13 (2.6) 3 (0.6) .132
Age-adjusted Charlson comorbidity index (score), mean (SD) and n (%) 4.9 (1.1) 5.2 (1.3)
0–4 124 (24.4) 106 (21.3) .097
4.1–6 304 (59.8) 297 (59.9) .231
>6 80 (15.7) 93 (18.8) .099
Method used to obtain cyto/pathological diagnosis, n (%)
EUS 427 (84.1) 406 (81.9) .128
US/CT-guided biopsy 81 (15.9) 90 (18.1) .126
Waiting times (d), mean (SD)
Time to first QDU visit – Time to admission 1.2 (0.3) 0.7 (0.2) <.001
QDU time for diagnosis – Admission time for diagnosis 4.3 (0.6) 4.1 (0.8) .163
Onward referral, n (%)
Outpatient specialist clinic (PMDU) 485 (95.4) 481 (97.0) .151
Admission from QDU 3 (0.6) n.a.
Primary care 12 (2.4) 9 (1.8) .203
Palliative care 8 (1.6) 6 (1.2) .217
Missing data: variables “Education” (QDU patients=1.2%, inpatients=0.9%), “Once-a-month income (€)” (QDU patients=1.9%, inpatients=2.0%), “Domestic situation” (QDU patients=0.4%, inpatients=
0.4%), “Age-adjusted Charlson comorbidity index (score)” (QDU patients=1.2%, inpatients=1.1%), “Waiting times” (QDU patients=0.3%, inpatients=0.4%).
CT= computed tomography, EUS=upper gastrointestinal endoscopic ultrasound, n.a.=not applicable, PMDU=pancreatic multidisciplinary unit, QDU=quick diagnosis unit, SD= standard deviation,
US=ultrasound.
∗
Self-reported home pay, including all pay components received by any home member, after tax subtraction.
† Usually, hepatomegaly of stony consistency.
‡ Hard, fixed lymphadenopathy.
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tumor (P= .221). Regional lymph nodes could not be identified in
imaging studies in 8.5% of QDU patients and 9.5% of inpatients.
The histological differentiation in 7.9% of QDU patients and
8.5% of inpatients was unknown for the pathologist. There were
several statistically significant differences regarding laboratory
results. Inpatients were more likely than QDU patients to have
higher serum levels of CA19.9, CEA, LDH, AST/SGOT, ALT/
SGPT, alkaline phosphatase, total bilirubin, creatinine, and CRP.
The levels of albumin and hemoglobin were significantly lower
in inpatients. There was some degree of missing data in the CA
19.9 and CEA determinations (Table 3).
3.3. Surgical characteristics
A total of 105 (10.5% of the total population) patients
underwent resection, corresponding to 60 QDU patients and
45 inpatients. Whereas 95 (54 QDU patients and 41 inpatients)
patients with I and II AJCC stages had an immediate resection,
4 of 6 QDU patients and 3 of 4 inpatients with a borderline
resectable tumor had a resection following neoadjuvant chemo-
radiotherapy (Table 4). The presence of preoperative jaundice
was significantly more common among inpatients than QDU
patients (P< .001), as it was having a total serum bilirubin level
>20mg/dL (P< .001) and an endoscopic biliary stent implanted
(P< .001). Inpatients were also more likely to have a mean tumor
size on surgical resection >2cm (P< .001), an N1 nodal stage on
resection (P< .001), a poorer histological grade on surgery
(P< .001), and vascular, lymphatic and perineural invasion on
surgical resection (P< .001 in all cases). The resection margins
were not significantly different between QDU patients and
inpatients (positive: 28.3% vs 33.3%, respectively). There was a
minor degree of missing data in the variable Charlson index
(Table 4).
3.4. Factors associated with hospitalization
On multivariate logistic regression analysis with adjustment
for other variables, 4 significant independent predictors of
hospitalization were identified: age ≥75 years, thrombophlebitis,
Table 2






Age, n (%) .168
<75 yr 326 (64.2) 312 (62.9)
≥75 yr 182 (35.8) 184 (37.1)
Smoking status, n (%)
Current 138 (27.2) 150 (30.2) .100
Ex-smoker 172 (33.9) 162 (32.7) .173
Never smoker 198 (39.0) 184 (37.1) .135
History of pancreatitis, n (%) .194
Yes 33 (6.5) 36 (7.3)
No 475 (93.5) 460 (92.7)
Family history of pancreatic cancer, n (%) .161
Yes 26 (5.1) 32 (6.5)
No 482 (94.9) 464 (93.5)
Body mass index (kg/m2), mean (SD)
and n (%)
26.9 (2.0) 27.3 (2.2) .132
<35 468 (92.1) 447 (90.1)
≥35 40 (7.9) 49 (9.9)




Yes 62 (12.2) 78 (15.7)
No 446 (87.8) 418 (84.3)
Heavy alcohol consumption, n (%)† .099
Yes 30 (5.9) 44 (8.9)
No 478 (94.1) 452 (91.1)
Missing data: variables “Smoking status” (QDU patients=1.7%, inpatients=1.6%), “Family history of
pancreatic cancer” (QDU patients=0.2%, inpatients=0.1%), “Body mass index (kg/m2)” (QDU
patients=2.2%, inpatients=2.0%), “Heavy alcohol consumption” (QDU patients=1.5%, inpatients
=1.4%).
QDU=quick diagnosis unit, SD = standard deviation.
∗
History of type 2 diabetes lasting for more than 10 yr.
†≥6drinks/d.
Table 3






ECOG performance score, mean (SD) and n (%) 0.3 (0.02) 0.6 (0.1) .067
0–<2 461 (90.7) 430 (86.7)
≥2–4 47 (9.3) 66 (13.3)
Primary tumor site, n (%) .032
Head 318 (62.6) 336 (67.7)
Body/tail 371 (37.4) 160 (32.3)
AJCC T stage, n (%) .048
T1 (2 cm) 140 (27.6) 114 (23.0)
T2 (>2 cm) 368 (72.4) 382 (77.0)
AJCC N stage, n (%)
N0 92 (18.1) 64 (12.9) .027
N1 368 (72.4) 382 (77.0) .049
Unknown (NX) 48 (9.4) 50 (10.1)
AJCC M stage, n (%) .120
M0 208 (40.9) 191 (38.5)
M1 300 (59.1) 305 (61.5)
AJCC staging, n (%)
Resectable 54 (10.6) 41 (8.3) .122
Borderline resectable 6 (1.2) 4 (0.8) .215
Unresectable (locally advanced) 148 (29.1) 146 (29.4) .221
Metastatic 300 (59.1) 305 (61.5) .120
Differentiation, n (%)
Well-differentiated 96 (18.9) 130 (26.2) <.001
Moderately differentiated 265 (52.2) 194 (39.1) <.001
Poorly differentiated 107 (21.1) 130 (26.2) .031
Unknown 40 (7.9) 42 (8.5)
Laboratory parameters, mean (SD)
Serum CA19.9 (U/mL) (NV <37) 338.4 (81.2) 491.3 (127.7) <.001
Serum CEA (ng/mL) (NV <5.0) 64.3 (14.2) 107.3 (25.6) <.001
Lactate dehydrogenase (U/L) (NV 450) 497.5 (99.5) 595.4 (131.9) .001
Albumin (g/L) (NV=34–48) 35.5 (4.2) 32.3 (5.3) <.001
WBC count (109/L) (NV=4.00–11.00) 9.72 (3.30) 10.65 (3.83) .123
Platelet count (109/L) (NV=130–400) 426.3 (102.3) 466.7 (116.7) .137
Hemoglobin (g/L) (NV=120–170) 119.2 (13.6) 107.1 (15.0) <.001
AST/SGOT (U/L) (NV 40) 124.6 (23.1) 253.7 (50.8) <.001
ALT/SGPT (U/L) (NV 40) 136.3 (26.5) 269.5 (59.7) <.001
Alkaline phosphatase (U/L) (NV 116) 185.9 (34.2) 331.6 (72.4) <.001
Total bilirubin (mg/dL) (NV <1.2) 2.2 (0.4) 5.3 (1.0) <.001
BUN 23.4 (6.3) 24.8 (6.9) .198
Creatinine (mg/dL) (NV=0.30–1.30) 0.91 (0.18) 1.24 (0.27) <.001
C-reactive protein (mg/dL) (NV <1.0) 2.8 (2.1) 4.2 (3.4) .042
Missing data: variables “ECOG performance score” (QDU patients=0.3%, inpatients=0.2%), “AJCC
N stage” (QDU patients=1.8%, inpatients=1.8%), “Differentiation” (QDU patients=0.9%,
inpatients=0.7%), “Serum CA19.9:” undetermined in 2.8% of QDU patients and 2.4% of
inpatients, “Serum CEA:” undetermined in 4.3% of QDU patients and 3.8% of inpatients.
AJCC=American Joint Committee on Cancer (7th Edition [2010]), ALT/SGPT= alanine
aminotransferase, AST/SGOT= aspartate aminotransferase, BUN=blood urea nitrogen, CA19.9=
carbohydrate antigen 19.9, CEA=carcinoembryonic antigen, ECOG=Eastern Cooperative Oncology
Group, M stage=metastatic stage, N stage=nodal stage, NV=normal value, T stage= tumor stage,
WBC=white blood cell.
Bosch et al. Medicine (2020) 99:11 Medicine
6
jaundice, and an ECOG performance score ≥2 to 4. The ORs and
95%CIs of each factor are listed in Table 5. Having jaundice was
the strongest predictor of admission on multivariate analysis (OR
9.12, 95% CI: 6.58–16.03; P< .001). The quality of the model
was assessed with the discrimination of the area under the ROC
curve, which was 0.886.
3.5. Results of cost analysis
Table 6 shows the mean costs per day of hospitalization, per
QDU visit, and per patient in inpatients and QDU patients.
Considering that the mean admission time to diagnosis of
inpatients was 4.1 (1.4) days and that the mean number of visits
of QDU patients during the QDU time to diagnosis was 1.02
(0.3), the total cost per hospitalized patient was €634.36 (80.56),
with 46.4%being attributable to personnel salaries and 44.2% to
diagnostic tests, and the total cost per QDU patient was €347.76
(48.69), with 66.7%being attributable to diagnostic tests, 18.2%
to ambulatory visits, and 13.7% to salaries. According to the
analysis, the total saving with QDU was €286.6 per patient.
There was some degree of missing data in the variables
therapeutic procedures, drugs and consumables, consultations,
and adverse events (see Table 6 footnote).
4. Discussion
This study revealed that diagnosis of pancreatic cancer is
similarly achieved by conventional hospitalization and a
hospital-based ambulatory quick diagnostic clinic, and that the
latter approach appears to be cost-effective.
The general characteristics of pancreatic adenocarcinoma were
largely consistent with known features. However, there were
several salient differences between the inpatient and QDU
cohorts. First, although the EDwas the main referral source in all
patients, QDU patients were more commonly referred from PC
than inpatients, which may be compatible with the more indolent
nature of pancreatic cancer in the QDU cohort. Second, in line
with this observation, the differences in the presenting symptoms
and signs between the 2 groups were consistent with a more
advanced stage of disease in inpatients than QDU patients. Third,
the differences became more evident when analyzing the
prognostic factors reported to influence survival in patients with
pancreatic cancer. The staging process revealed that inpatients
were significantly more likely than QDU patients to have a
greater tumor dimension, nodal disease, poor differentiation, and
higher serum levels of laboratory parameters implicated in the
prognosis of pancreatic cancer, more specifically CA19.9.
However, the frequency of metastatic and locally advanced
disease did not differ significantly between groups. Also, even
though one might expect to find a higher occurrence of resectable
tumors amongQDU patients, no differences were observed in the
proportion of resectable cases between QDU patients and
inpatients. These observations may be explained by the
“intrinsic” aggressiveness of pancreatic adenocarcinoma.
In our study, inpatients were more likely than QDU patients to
be referred directly to the ED. Due to diagnostic difficulties by PC
physicians in the presence of atypical symptoms and because
inpatients have preferential access to examinations, patients
with suspected cancer are frequently referred to the ED for
admission.[12,14,46,47] It has been reported that a substantial
proportion of cancer patients are diagnosed through an
emergency presentation [48–50] and that patients with “harder-
to-suspect” cancers with atypical symptoms such as pancreatic
and stomach cancer and multiple myeloma have a higher
proportion of emergency presentations.[9,46,51]
No previous study has reported the associated costs of an
ambulatory versus inpatient setting for the diagnosis of
pancreatic adenocarcinoma. The cost analysis was central to
our study aims. The cost of the diagnostic evaluation in inpatients
was almost the double that of QDU patients and savings were
achieved at a similar time to diagnosis. It should be noted that
nearly 50% of the costs incurred by the inpatient setting versus








Age at surgery (yr), mean (SD) and n (%) 66.7 (15.5) 67.2 (16.7)
54 9 (15.0) 4 (8.9) .249
55–64 22 (36.7) 17 (37.8) .450
65–74 28 (46.7) 22 (48.9) .409
≥75 1 (1.7) 2 (4.4) .388
Sex, n (%) .473
Females 29 (48.3) 22 (48.9)
Males 31 (51.7) 23 (51.1)
Age-adjusted Charlson comorbidity index (score),
mean (SD) and n (%)
3.0 (0.6) 3.3 (0.7)
0–4 15 (25.0) 10 (22.2) .385
4.1–6 36 (60.0) 27 (60.0) .494
>6 9 (15.0) 8 (17.8) .386
ECOG performance score, mean (SD) and n (%) 0.4 (0.05) 0.7 (0.2) .339
0–<2 53 (88.3) 38 (84.4)
>2–4 7 (11.7) 7 (15.6)
Preoperative jaundice, n (%) 11 (18.3) 23 (51.1) <.001
Total bilirubin >20 mg/dL, n (%) 2 (3.3) 10 (22.1) <.001
Preoperative endoscopic biliary stent, n (%) 1 (1.7) 9 (20.0) <.001
Resectability according to AJCC system, n (%)
Resectable 54 (90.0) 41 (91.1) .448
Borderline resectable 6 (10.0) 4 (8.9) .452
Resected 4 (6.7) 3 (6.7) .495
Number of eligible patients who underwent
pancreatic resection, n (%)
58 (96.7) 44 (97.8) .451
Primary tumor site on surgical resection, n (%) .268
Head 38 (63.3) 31 (68.9)
Body/tail 22 (36.7) 14 (31.1)
Tumor size on surgical resection, n (%) <.001
2 cm 18 (30.0) 6 (13.3)
>2 cm 42 (70.0) 39 (86.7)
Nodal stage on surgery, n (%)
N0 18 (30.0) 4 (8.9) <.001
N1 42 (70.0) 41 (91.1)
Histological grade, n (%)
Good 15 (25.0) 8 (17.8) .200
Moderate 29 (48.3) 15 (33.3) <.001
Poor 16 (26.7) 22 (48.9) <.001
Vascular invasion on surgical resection, n (%) 14 (23.3) 19 (42.2) <.001
Lymphatic invasion on resection, n (%) 19 (31.7) 21 (46.7) <.001
Perineural invasion on resection, n (%) 31 (51.7) 41 (91.1) <.001
Adjusted preoperative serum CA19.9 level
(U/mL), mean (SD)
213.4 (42.5) 329.5 (67.2) <.001
Resection margins, n (%) .293
Negative 43 (71.7) 30 (66.7)
Positive 17 (28.3) 15 (33.3)
Missing data: variables “Charlson index (score)” (QDU patients=1.0%, inpatients=0.8%).
CA19.9=carbohydrate antigen 19.9, ECOG=Eastern Cooperative Oncology Group, QDU=quick
diagnosis unit, SD = standard deviation, WBC=white blood cell.
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Table 5
Univariate and multivariate logistic regression analysis of factors associated with emergency admission against factors associated with
referral from the emergency department to the quick diagnosis unit.
Univariate analysis Multivariate analysis
Variable OR 95% CI P-value OR 95% CI P-value
Sex (vs females)
Males 1.07 0.72–1.49 .188 1.02 0.64–1.36 .143
Females Reference
Age (vs 54 years)
54 yr Reference
55–64 yr 1.01 0.82–1.37 .123 1001 0.61–1.30 .087
65–74 yr 1.36 0.95–1.78 .177 1.23 0.84–1.71 .239
>75 yr 4840 3.48–8.54 .003 4.40 3.31–8.19 .012
Education (vs upper secondary or professional training)
No schooling 1.11 0.90–1.52 .096 1.10 0.87–1.50 .112
Primary or lower secondary 1.02 0.92–1.22 .157 1.00 091–1.19 .214
Upper secondary or professional training Reference
University 0.96 0.80–1.33 .195 0.90 071–1.25 .234
Domestic situation (vs living with partner)
Living alone 1.47 1.25–2.28 .023 1.44 1.20–1.99 .073
Living with partner Reference
Other 1.01 0.99–1.30 .248
Presenting symptoms and signs
Weight loss 1.51 1.24–2.49 .044 1.48 1.17–2.40 .107
Weight loss, asthenia, and anorexia 2.17 1.90–2.91 .034 1.96 1.80–2.89 .055
Abdominal pain 1.64 1.36–2.15 .021 1.42 1.24–2.18 .082
Back pain 1.26 0.81–2.07 .047 1.13 0.79–1.92 .066
Nausea/vomiting 1.19 0.72–1.51 .190 1102 0.64–1.44 .197
Lethargy/depression 1.02 0.77–1.86 .202
Thrombophlebitis 2.32 1.96–3.20 .031 2.07 1.77–2.86 .041
Jaundice 9.28 6.70–17.14 <.001 9.12 6.58–16.03 <.001
New-onset diabetes 1.66 1.23–2.53 .038 1.52 1.04–2.45 .057
Abdominal mass 1.85 1.36–2.94 .044 1.70 1.33–2.81 .063
Hepatomegalya 1.14 0.96–1.42 .094 1.06 0.90–1.35 .072
Peripheral lymphadenopathyb 1.01 0.94–1.15 .173 0.96 0.90–1.14 .194
Age-adjusted Charlson comorbidity index (vs 0–4)
0–4 Reference
4.1–6 1.157 0.802–1.518 .075 1.134 0.779–1.485 .084
>6 1.489 1.137–2.056 .069 1.325 0.926–1.989 .058
ECOG performance score (vs 0–<2)
0-<2 Reference
>2–4 1.328 0.879–1.952 .059 1.304 0.804–1.905 .044
Risk factors
Smoking status (vs never smoker)
Current 1.138 0.966–1.474 .133 1.027 0.856–1.349 .148
Ex-smoker 1.028 0.747–1.775 .231
Never smoker Reference
Body mass index (vs <35 kg/m2)
≥35 kg/m2 1.556 1.113–2.470 .073 1.537 1.048–2.387 .092
<35 kg/m2 Reference
Long-lasting type 2 diabetes mellitus (vs none)
Yes 1.076 0.855–1.475 .327
No Reference
Heavy alcohol consumption (vs none)
Yes 1.133 0.909–1.598 .109 1.038 0.821–1.486 .128
No Reference
Laboratory parameters
Serum CA19.9 >122.5 1.223 0.807–1.739 .081 1.151 0.725–1.678 .075
LDH ≥589.2 U/L 1.205 0.784–1.622 .015 1.170 0.653–1.582 .093
Albumin 33.3 g/L 1.176 0.732–1.509 .037 1.015 0.684–1.444 .072
Hemoglobin 111.9 g/L 1.200 0.912–1.821 .084 1.181 0.899–1.787 .081
AST/SGOT ≥190.7 U/L 1.134 0.815–1.678 .095 1.005 0.764–1.532 .112
ALT/SGPT ≥207.3 U/L 1.196 1.052–1.469 .012 1.009 0.881–1.340 .055
AP ≥262.1 U/L 1.182 1.041–1.527 .099 1.031 0.997–1.472 .099
Total bilirubin ≥3.9 mg/dL 2.133 1.764–2.980 .033 1.888 1.491–2.626 .071
Creatinine ≥1.09 mg/dL 1.476 1.035–2.124 .031 1.330 0.897–1.968 .103
CRP ≥4.0 mg/dL 1.344 0.912–1.883 .186 1.272 0.875–1.734 .217
AP= alkaline phosphatase, ALT/SGPT= alanine aminotransferase, AST/SGOT= aspartate aminotransferase, CA19.9= carbohydrate antigen 19.9, CI= confidence interval, CRP=C-reactive protein, ECOG=
Eastern Cooperative Oncology Group, LDH= lactate dehydrogenase, OR= odds ratio.
a Usually, hepatomegaly of stony consistency.
b Hard, fixed lymphadenopathy.
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Although this finding may suggest an excess of staff in inpatient
wards, several factors were likely involved during the stay of these
patients which were not accounted for in the cost analysis.
Patients with pancreatic cancer may require admission for
diagnosis due to severe symptoms that may not be effectively
managed in a hospital-based ambulatory unit that is considerably
less staffed. The cost of an inpatient diagnosis may thus be worth
if there are other complementary or competing diagnoses that are
treated or managed at the same time.
4.1. Strengths and limitations
The strengths of our study include the size of the sample (N=
1004), with a similar proportion of QDU patients and inpatients,
and its duration (13 years). But it has limitations. Asmentioned, it
is likely that the cost analysis did not account for several
hospitalization-related factors. The clinical and cytopathological
information was carefully reviewed and registered, but some
details may not have been captured and possible confounders
were not determined, which is consistent with the retrospective
design of the study. The exclusion of patients without complete
information and the presence of missing data might have biased
the results, but the low rate of 2 factors meant that study results
were unlikely affected. The outcomes were not analyzed and the
potential differences between the 2 cohorts could not be analyzed
either. Finally, the management of patients referred to ambula-
tory clinics or admitted for investigation of clinical manifes-
tations such as to those reported here and who have an eventual
diagnosis of pancreatic cancer can be different in other settings, a
circumstance that depends on various factors such as the type of
hospital, the available resources, or the institution traditions.
5. Conclusions
In this study, the effectiveness of a hospital-based ambulatory
clinic for the diagnosis of pancreatic adenocarcinoma was similar
to that of hospitalization. Although there were no differences in
the time to diagnosis between the 2 approaches, the costs of
inpatients’ diagnosis were nearly the double than those of QDU
patients. Because the high costs of hospitalization and the
reported advantages for patients of a hospital-based ambulatory
versus inpatient management,[15,17] an ambulatory instead of an
inpatient diagnostic evaluation may be preferable in patients with
suspected pancreatic cancer. However, it may be argued that
admission has an added value for diagnosis since it is associated
with issues which may not be properly treated or managed in an
ambulatory setting.
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Table 6
Mean costs (€) of QDU patients (n=508) and inpatients (n=496).
Item Inpatients QDU patients Cost per patient (€), mean (SD)
One-d stay One visit Inpatients
∗
QDU patients† P-value
Staff wages‡ 71.83x 46.77 294.50 (18.26) 47.71 (4.15) <.001
QDU visitsjj n.a. 62.00 n.a. 63.24 (5.39)
Diagnostic examinations¶ 68.44 227.33 280.60 (20.44) 231.88 (12.52) <.001
Therapeutic procedures# 0.42 0.18 1.72 (0.28) 0.18 (0.02) <.001
Pharmaceuticals and consumables 4.55 0.32 18.66 (3.09) 0.33 (0.06) <.001
Consultations
∗∗
0.56 0.15 2.30 (0.32) 0.15 (0.03) <.001
Adverse events 0.32 0.03 1.31 (0.41) 0.03 (0.01) <.001
Catering 3.97 n.a. 16.28 (0.88) n.a.
Cleaning 2.04 0.72 8.36 (0.67) 0.73 (0.05) <.001
Laundry 1.26 0.25 5.17 (0.36) 0.26 (0.02) <.001
Travel†† n.a. 0.08 n.a. 0.08 (0.02) <.001
Maintenance 0.16 0.05 0.66 (0.07) 0.05 (0.01) <.001
Administrative 0.09 0.02 0.37 (0.03) 0.02 (0.01) <.001
Depreciation 1.08 3.04 4.43 (0.89) 3.10 (0.61) <.001
Total costs 154.72 340.94 634.36 (80.56) 347.76 (48.69) <.001
Missing data: variables “Therapeutic procedures” (QDU patients=0.6%, inpatients=0.8%), “Pharmaceuticals and consumables” (QDU patients=1.7%, inpatients=1.9%), “Consultations” (QDU patients=
2.5%, inpatients=2.0%), “Adverse events” (QDU patients=1.1%, inpatients=1.0%).
QDU=quick diagnosis unit, SD = standard deviation.
∗
Mean (SD) admission time for diagnosis: 4.1 (1.4) d.
†Mean (SD) number of visits during the QDU time for diagnosis: 1.02 (0.3).
‡ Details about wages of staff at inpatient wards and QDU are explained in Methods (section “Resource use data collection and cost analysis”).
xMatches wage fractions of staff responsible for 12.5 patients at inpatient wards (25 beds per ward).
jj Costs of QDU visits were based on Catalan Health Service fees.
¶ Costs of diagnostic examinations corresponded to hospital tariffs.
# Corresponds to costs of procedures such as therapeutic thoracentesis.
∗∗
Costs of consultations with hospital employees (eg, physicians, social workers, or dieticians).
†† Costs generated by transport to and from QDU of patients (and accompanying personnel).
Bosch et al. Medicine (2020) 99:11 www.md-journal.com
9
Project administration: Mar Guerra-García, Neus Guasch.
Resources: Pedro Moreno, Neus Guasch, Alfons López-Soto.
Supervision: Xavier Bosch.
Validation: Xavier Bosch, Mar Guerra-García, Alfons López-
Soto.
Visualization: Pedro Moreno, Neus Guasch, Alfons López-Soto.
Writing – original draft: Xavier Bosch.
References
[1] Kamisawa T, Wood LD, Itoi T, et al. Pancreatic cancer. Lancet
2016;388:73–85.
[2] Ducreux M, Cuhna AS, Caramella C, et al. ESMO Guidelines
CommitteeCancer of the pancreas: ESMO clinical practice guidelines
for diagnosis, treatment and follow-up. Ann Oncol 2015;26(Suppl 5):
v56–68.
[3] Ryan DP, Hong TS, Bardeesy N. Pancreatic adenocarcinoma. N Engl J
Med 2014;371:1039–49.
[4] Maroni L, Ravaioli M, Pinna AD. Why is pancreatic adenocarcinoma
not screened for earlier? Expert Rev Anticancer Ther 2016;16:
1003–4.
[5] Hansen RP, Vedsted P, Sokolowski I, et al. Time intervals from first
symptom to treatment of cancer: a cohort study of 2,212 newly
diagnosed cancer patients. BMC Health Serv Res 2011;11:284.
[6] National Guideline Alliance (UK). Pancreatic cancer in adults: diagnosis
and management. National Institute for Health and Care Excellence:
Clinical Guidelines. London: National Institute for Health and Care
Excellence (UK); 2018 Feb.
[7] Bond-Smith G, Banga N, Hammond TM, et al. Pancreatic adenocarci-
noma. BMJ 2012;344:e2476.
[8] Evans J, Chapple A, Salisbury H, et al. It can’t be very important because
it comes and goes”–patients’ accounts of intermittent symptoms
preceding a pancreatic cancer diagnosis: a qualitative study. BMJ Open
2014;4:e004215.
[9] Lyratzopoulos G, Abel GA, McPhail S, et al. Measures of promptness of
cancer diagnosis in primary care: secondary analysis of national audit
data on patients with 18 common and rarer cancers. Br J Cancer
2013;108:686–90.
[10] Lyratzopoulos G, Saunders CL, Abel GA, et al. The relative length of the
patient and the primary care interval in patients with 28 common and
rarer cancers. Br J Cancer 2015;112(Suppl 1):S35–40.
[11] Lyratzopoulos G, Wardle J, Rubin G. Rethinking diagnostic delay in
cancer: how difficult is the diagnosis? BMJ 2014;349:g7400.
[12] Bosch X, Aibar J, Capell S, et al. Quick diagnosis units: a potentially
useful alternative to conventional hospitalisation. Med J Aust 2009;
191:496–8.
[13] Bosch X, Jordán A, Coca A, et al. Quick diagnosis units versus
hospitalization for the diagnosis of potentially severe diseases in Spain. J
Hosp Med 2012;7:41–7.
[14] Bosch X, Jordán A, López-Soto A. Quick diagnosis units: avoiding
referrals from primary care to the ED and hospitalizations. Am J Emerg
Med 2013;31:114–23.
[15] Sanclemente-Ansó C, Salazar A, Bosch X, et al. Perception of quality of
care of patients with potentially severe diseases evaluated at a distinct
quick diagnostic delivery model: a cross-sectional study. BMC Health
Serv Res 2015;15:434.
[16] Bosch X, Moreno P, Ríos M, et al. Comparison of quick diagnosis units
and conventional hospitalization for the diagnosis of cancer in Spain: a
descriptive cohort study. Oncology 2012;83:283–91.
[17] Bosch X, Sanclemente-Ansó C, Escoda O, et al. Time to diagnosis and
associated costs of an outpatient vs inpatient setting in the diagnosis of
lymphoma: a retrospective study of a large cohort of major lymphoma
subtypes in Spain. BMC Cancer 2018;18:276.
[18] Bosman FT, Carneiro F, Hruban RH, Theise ND.WHOClassification of
Tumors of the Digestive System. 4th ed.Lyon (France): International
Agency for Research on Cancer; 2010;381–98.
[19] Charlson ME, Pompei P, Ales KL, et al. A new method of classifying
prognostic comorbidity in longitudinal studies: development and
validation. J Chronic Dis 1987;40:373–83.
[20] Charlson M, Szatrowski TP, Peterson J, et al. Validation of a combined
comorbidity index. J Clin Epidemiol 1994;47:1245–51.
[21] Wolfgang CL, Herman JM, Laheru DA, et al. Recent progress in
pancreatic cancer. CA Cancer J Clin 2013;63:318–48.
[22] Pancreatric Section, British Society of Gastroenterology; Pancreatic
Society of Great Britain and Ireland; Association of Upper Gastrointes-
tinal Surgeons of Great Britain and Ireland; Royal College of
Pathologists; Special Interest Group for Gastro-Intestinal Radiology-
Guidelines for the management of patients with pancreatic cancer
periampullary and ampullary carcinomas. Gut 2005;54(Suppl 5):v1–6.
[23] Shrikhande SV, Barreto SG, Goel M, et al. Multimodality imaging of
pancreatic ductal adenocarcinoma: a review of the literature. HPB
(Oxford) 2012;14:658–68.
[24] Arslan AA, Helzlsouer KJ, Kooperberg C, et al. Pancreatic Cancer
Cohort Consortium (PanScan)Anthropometric measures, body mass
index, and pancreatic cancer: a pooled analysis from the Pancreatic
Cancer Cohort Consortium (PanScan). Arch Intern Med 2010;170:791–
802.
[25] Le N, Sund M, Vinci A. GEMS Collaborating group of Pancreas
2000Prognostic and predictive markers in pancreatic adenocarcinoma.
Dig Liver Dis 2016;48:223–30.
[26] Tas F, Sen F, Odabas H, et al. Performance status of patients is the major
prognostic factor at all stages of pancreatic cancer. Int J Clin Oncol
2013;18:839–46.
[27] Kang CM, Kim JY, Choi GH, et al. The use of adjusted preoperative CA
19-9 to predict the recurrence of resectable pancreatic cancer. J Surg Res
2007;140:31–5.
[28] Sohn TA, Yeo CJ, Cameron JL, et al. Resected adenocarcinoma of the
pancreas-616 patients: results, outcomes, and prognostic indicators. J
Gastrointest Surg 2000;4:567–79.
[29] Stocken DD, Hassan AB, Altman DG, et al. Modelling prognostic factors
in advanced pancreatic cancer. Br J Cancer 2008;99:883–93.
[30] Arnachellum RP, Cariou M, Nousbaum JB, et al. Pancreatic adenocar-
cinoma in the Finistère area, France, between 2002 and 2011 (1002
Cases): population characteristics, treatment and survival. Pancreas
2016;45:953–60.
[31] Butturini G, Stocken DD, Wente MN, et al. Pancreatic Cancer Meta-
Analysis GroupInfluence of resection margins and treatment on survival
in patients with pancreatic cancer: meta-analysis of randomized
controlled trials. Arch Surg 2008;143:75–83.
[32] Brown KM, Domin C, Aranha GV, et al. Increased preoperative platelet
count is associated with decreased survival after resection for
adenocarcinoma of the pancreas. Am J Surg 2005;189:278–82.
[33] Kim YC, Kim HJ, Park JH, et al. Can preoperative CA19-9 and CEA
levels predict the resectability of patients with pancreatic adenocarcino-
ma? J Gastroenterol Hepatol 2009;24:1869–75.
[34] Strasberg SM, Gao F, Sanford D, et al. Jaundice: an important, poorly
recognized risk factor for diminished survival in patients with
adenocarcinoma of the head of the pancreas. HPB (Oxford) 2014;
16:150–6.
[35] Olson SH, Kurtz RC. Epidemiology of pancreatic cancer and the role of
family history. J Surg Oncol 2013;107:1–7.
[36] Winter JM, Yeo CJ, Brody JR. Diagnostic, prognostic, and predictive
biomarkers in pancreatic cancer. J Surg Oncol 2013;107:15–22.
[37] Haas M, Heinemann V, Kullmann F, et al. Prognostic value of CA 199,
CEA, CRP, LDH and bilirubin levels in locally advanced and metastatic
pancreatic cancer: results from a multicenter, pooled analysis of patients
receiving palliative chemotherapy. J Cancer Res Clin Oncol 2013;
139:681–9.
[38] Ansari D, Bauden M, Bergström S, et al. Relationship between tumour
size and outcome in pancreatic ductal adenocarcinoma. Br J Surg
2017;104:600–7.
[39] Ong SL, Garcea G, Thomasset SC, et al. Surrogate markers of
resectability in patients undergoing exploration of potentially resecta-
blepancreatic adenocarcinoma. J Gastrointest Surg 2008;12:1068–73.
[40] Public Health England. National Cancer Intelligence Network Short
Report. Routes to diagnosis 2015 update: pancreatic cancer. February,
2016.
[41] Drummond MF, Sculpher MJ, Claxton K, et al. Methods for the
Economic Evaluation of Health Care Programmes. 4th ed.Oxford:
Oxford University Press; 2015.
[42] Finkler SA, Ward DM, Baker JJ. Essentials of Cost Accounting for
Health Care Organizations. 3rd ed. New York: Jones & Bartlett
Learning; 2007.
[43] Tan SS, Rutten FF, van Ineveld BM, et al. Comparing methodologies for
the cost estimation of hospital services. Eur J Health Econ 2009;10:
39–45.
[44] Bosch X, Palacios F, Inclán-Iríbar G, et al. Quick diagnosis units or
conventional hospitalisation for the diagnostic evaluation of severe
Bosch et al. Medicine (2020) 99:11 Medicine
10
anaemia: a paradigm shift in public health systems? Eur J Intern Med
2012;23:159–64.
[45] Brito-Zerón P, Nicolás-Ocejo D, Jordán A, et al. Diagnosing unexplained
fever: can quick diagnosis units replace inpatient hospitalization? Eur J
Clin Invest 2014;44:707–18.
[46] Hamilton W. Emergency admissions of cancer as a marker of diagnostic
delay. Br J Cancer 2012;107:1205–6.
[47] Sheringham JR, Georghiou T, Chitnis XA, et al. Comparing primary and
secondary health-care use between diagnostic routes before a colorectal
cancer diagnosis: cohort study using linked data. Br J Cancer 2014;
111:1490–9.
[48] Abel GA, Shelton J, Johnson S, et al. Cancer-specific variation in
emergency presentation by sex, age and deprivation across 27 common
and rarer cancers. Br J Cancer 2015;112(Suppl 1):S129–36.
[49] Elliss-Brookes L, McPhail S, Ives A, et al. Routes to diagnosis for cancer -
determining the patient journey using multiple routine data sets. Br J
Cancer 2012;107:1220–6.
[50] Public Health England. National Cancer Intelligence Network Data
Briefing. Routes to Diagnosis: Exploring Emergency Presentations. 2013.
[51] Lyratzopoulos G, Neal RD, Barbiere JM, et al. Variation in number of
general practitioner consultations before hospital referral for cancer:
findings from the 2010 National Cancer Patient Experience Survey in
England. Lancet Oncol 2012;13:353–65.
Bosch et al. Medicine (2020) 99:11 www.md-journal.com
11
